

Supplementary Information for

De novo biosynthesis of bioactive isoflavonoids by engineered yeast cell factories

Quanli Liu^{1,2#}, Yi Liu^{1,2#}, Gang Li^{1,2}, Otto Savolainen^{1,3,4}, Yun Chen^{1,2}, Jens Nielsen^{1,2,5,6*}

¹Department of Biology and Biological Engineering, Kemivägen 10, Chalmers University of Technology, SE41296 Gothenburg, Sweden

²Novo Nordisk Foundation Center for Biosustainability, Chalmers University of Technology, SE41296 Gothenburg, Sweden

³Chalmers Mass Spectrometry Infrastructure, Kemivägen 10, Chalmers University of Technology, SE41296 Gothenburg, Sweden


⁴Institute of Public Health and Clinical Nutrition, University of Eastern Finland, FI70211 Kuopio, Finland

⁵Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, DK2800 Kongens Lyngby, Denmark


⁶BioInnovation Institute, Ole Maaløes vej 3, DK2200 Copenhagen N, Denmark.

#These authors contributed equally: Quanli Liu, Yi Liu.


* Corresponding author E-mail: nielsenj@chalmers.se




Supplementary Fig. 1. Main subfamilies and core skeletons of common flavonoids. Isoflavonoids contain the common C6-C3-C6 flavonoid skeleton and are characterized by having the B-ring connected at C3 rather than C2 position of the ring C, compared to other flavonoid subclasses




Supplementary Fig. 2. Flowchart of yeast strain construction in this study.




Supplementary Fig. 3. Characterization and comparison of metabolic enzymes for production of LIG.
a Genetic characteristics of generated yeast strains. For the source of selected plant genes: *Ms*, *Medicago sativa*; *Rs*, *Rhododendron simsii*; *Ha*, *Hypericum androsaemum*; *Ph*, *Petunia hybrida*; *Sb*, *Scutellaria baicalensis*; *Ps*, *Paeonia suffruticosa*. See Fig. 1 and 2 legends regarding gene details and abbreviations of other plant species. **b-c** Production profiles of intermediates ISOLIG and LIG and by-product NAG produced by yeast strains harboring different combination of biosynthetic enzymes 4CL, CHS, CHR and CHI. Cells were grown in defined minimal medium with 30 g L⁻¹ glucose as the sole carbon source, and cultures were sampled after 72 h of growth for metabolite detection. All data represent the mean of n = 3 biologically independent samples and error bars show standard deviation. The source data underlying figures **b-c** are provided in a Source Data file.




Supplementary Fig. 4. Production profiles of yeast strains overexpressing different biosynthetic genes encoding 2-HIS and HID. Titers of DEIN, its intermediates and by-products are shown. Cells were grown in defined minimal medium with 30 g L⁻¹ glucose as the sole carbon source, and cultures were sampled after 72 h of growth for metabolite detection. All data represent the mean of n = 3 biologically independent samples and error bars show standard deviation. The source data are provided in a Source Data file.




Supplementary Fig. 5. Growth profiles of strains generated by engineering ER homeostasis. Cells were grown in defined minimal medium with 30 g L⁻¹ glucose as the sole carbon source, and cultures were sampled after 72 h of growth for OD600 measurement. Statistical analysis was performed by using Student's *t* test (two-tailed; two-sample unequal variance; **p* < 0.05, ***p* < 0.01, ****p* < 0.001). All data represent the mean of *n* = 3 biologically independent samples and error bars show standard deviation. The source data are provided in a Source Data file.




Supplementary Fig. 6. Residual precursor *p*-HCA of engineered yeast strains. The *p*-HCA profiles of strains generated by engineering heme metabolism (a), ER homeostasis (b) and the cofactor NADPH generation (c) were measured. See Fig. 4 for more strain and gene details. Cells were grown in defined minimal medium with 30 g L⁻¹ glucose as the sole carbon source, and cultures were sampled after 72 h of growth for metabolite detection. All data represent the mean of *n* = 3 biologically independent samples and error bars show standard deviation. The source data are provided in a Source Data file.




Supplementary Fig. 7. Production profiles of engineered yeast strains. Titer of DEIN, its intermediates and by-products of strains generated by engineering heme metabolism (a), ER homeostasis (b) and cofactor NADPH generation (c) are shown. See Fig. 4 for more strain and gene details. Cells were grown in defined minimal medium with 30 g L⁻¹ glucose as the sole carbon source, and cultures were sampled after 72 h of growth for metabolite detection. All data represent the mean of n = 3 biologically independent samples and error bars show standard deviation. The source data are provided in a Source Data file.




Supplementary Fig. 8. Metabolic intermediates and by-product produced by strains I01 expressing DEIN pathway under the control of inducible GAL promoters. Cells were grown in defined minimal medium with 30 g L⁻¹ glucose as the sole carbon source and 10 g L⁻¹ galactose as the inducer. Cultures were sampled after 72 h of growth for metabolite detection. All data represent the mean of n = 3 biologically independent samples and error bars show standard deviation. The source data are provided in a Source Data file.




Supplementary Fig. 9. Metabolic intermediates and by-product produced by strains expressing fused enzymes E3 (GmCHS8)-Linker-E4 (GmCHR5) and E4 (GmCHR5)-Linker-E5(GmCHI1B2). Cells were grown in defined minimal medium with 30 g L⁻¹ glucose as the sole carbon source and 10 g L⁻¹ galactose as the inducer. Cultures were sampled after 72 h of growth for metabolite detection. All data represent the mean of n = 3 biologically independent samples and error bars show standard deviation. The source data are provided in a Source Data file.




Supplementary Fig. 10. Effect of 5-ALA supplementation on DEIN production and cell growth. The production of DEIN (**a**) and optical density at 600nm (**b**) were measured. Cells were grown in defined minimal medium with 30 g L⁻¹ glucose as the sole carbon source and 10 g L⁻¹ galactose as the inducer. Cultures were sampled after 72 h of growth for metabolite detection. Statistical analysis was performed by using Student's *t* test (two-tailed; two-sample unequal variance; **p* < 0.05, ***p* < 0.01, ****p* < 0.001). All data represent the mean of *n* = 3 biologically independent samples and error bars show standard deviation. The source data are provided in a Source Data file.




Supplementary Fig. 11. DEIN production of strains integrated with strategies altering NADPH generation. See Fig. 4 for more strain and gene information. Cells were grown in defined minimal medium with 30 g L⁻¹ glucose as the sole carbon source and 10 g L⁻¹ galactose as the inducer. Cultures were sampled after 72 h of growth for metabolite detection. Statistical analysis was performed by using Student's *t* test (two-tailed; two-sample unequal variance; **p* < 0.05, ***p* < 0.01, ****p* < 0.001). All data represent the mean of *n* = 3 biologically independent samples and error bars show standard deviation. The source data are provided in a Source Data file.



Supplementary Fig. 12. Glucose release profile of FeedBeads in defined minimal medium. Six tablets of FeedBeads (FB), a slow release system for glucose, were placed in a 125 ml non-baffled flask containing 15 ml minimal medium and incubated at 30 °C with an agitation rate of 220 rpm. 50 µl cultures were removed from the flask at indicated time points for quantification of glucose concentration. All data represent the mean of n = 3 biologically independent samples and error bars show standard deviation. The source data are provided in a Source Data file.




Supplementary Fig. 13. Phenotypes of strain I25 under cultivations with different modes of carbon source supply. See Fig. 6 for more strain details. The production of DEIN, intermediates and by-products (**a**) and optical density at 600nm (**b**) were measured. Cells were grown in defined minimal medium with 30 g L⁻¹ glucose (Batch) or six tablets of FB as the sole carbon source and 10 g L⁻¹ galactose as the inducer. Cultures were sampled after 72 h (Batch) or 90 h (FB) of growth for metabolite detection. Statistical analysis was performed by using Student's *t* test (two-tailed; two-sample unequal variance; **p* < 0.05, ***p* < 0.01, ****p* < 0.001). All data represent the mean of *n* = 3 biologically independent samples and error bars show standard deviation. The source data are provided in a Source Data file.




Supplementary Fig. 14. Production profiles of strains harboring regulated expression of *FAS1* gene.

The production of DEIN, intermediates and by-products were measured. Cells were grown in defined minimal medium with six tablets of FB as the sole carbon source and 10 g L⁻¹ galactose as the inducer. Cultures were sampled after 90 h of growth for metabolite detection. All data represent the mean of n = 3 biologically independent samples and error bars show standard deviation. The source data are provided in a Source Data file.




Supplementary Fig. 15. Production profiles of strains integrated with strategies regulating the *GAL* induction. The production of DEIN, intermediates and by-products were measured. Cells were grown in defined minimal medium with six tablets of FB as the sole carbon source and 10 g L⁻¹ galactose as the inducer. Cultures were sampled after 90 h of growth for metabolite detection. All data represent the mean of n = 3 biologically independent samples and error bars show standard deviation. The source data are provided in a Source Data file.




Supplementary Fig. 16. Growth profiles of *S. cerevisiae* under different concentrations of DEIN.


Overnight precultures of background strain IMX581 were diluted and transferred to 96-well microplates containing 250 μ l defined minimal medium with the initial OD600 of 0.1. The cultures were grown at 30°C with 250 rpm shaking, and the OD600 was automatically measured by Growth Profiler 960 (EnzyScreen). All data represent the mean of $n = 3$ biologically independent samples and error bars show standard deviation. The source data are provided in a Source Data file.



Supplementary Fig. 17. LC-MS characterization of glycosylated chemicals. Extracted ion chromatograms at m/z^+ 417.1180 are shown as evidence for the production of PIN and DIN in engineered yeast strains. LC-MS profiles are shown for the analysis of PIN standard (a), the PIN product from *PIUGT43*-expressing strain E03 extracts (b), DIN standard (c) and the DIN product from the *GmUGT4*-expressing strain E06 extracts (d). Cells were grown in defined minimal medium with 30 g L⁻¹ glucose as the sole carbon source, and cultures were sampled after 72 h of growth for LC-MS analysis.



Supplementary Fig. 18. Production of glycosylated chemicals. **a** Schematic view of the engineered metabolic pathways for the biosynthesis of glucosides DIN and PIN, and relevant by-products. See Fig. 1 legend regarding abbreviations of metabolites and gene details. Production profiles of G8G (**b**) and GIN (**c**) in DEIN hyper-producing strain I34 background with or without increased UDP-glucose supply. Cells were grown in defined minimal medium with six tablets of FB as the sole carbon source and 10 g L⁻¹ galactose as the inducer. Cultures were sampled after 90 h of growth for metabolite detection. All data represent the mean of $n = 3$ biologically independent samples and error bars show standard deviation. The source data underlying figures **b-c** are provided in a Source Data file.



Supplementary Fig. 19. Toxicity for growth of *S. cerevisiae* of DEIN glucosides. Growth profiles of background strain IMX581 under different concentrations of PIN (**a**) and DIN (**b**) were evaluated. Overnight precultures were diluted and transferred to 96-well microplates containing 250 μ l defined minimal medium with the initial OD600 of 0.1. The cultures were grown at 30°C with 250 rpm shaking, and the OD600 was automatically measured by Growth Profiler 960 (EnzyScreen). All data represent the mean of $n = 3$ biologically independent samples and error bars show standard deviation. The source data are provided in a Source Data file.

Supplementary Table 1. Promoters used for fine-tuning the transcription of *FAS1* gene in yeast

No.	Alias	Activity on Glucose^a
<i>Native</i>	<i>FAS1p</i>	100%
<i>1</i>	<i>PFK2p</i>	87%
<i>2</i>	<i>BGL2p</i>	83%
<i>3</i>	<i>HXT2p</i>	72%
<i>4</i>	<i>QCR9p</i>	63%
<i>5</i>	<i>PRE2p</i>	61%
<i>6</i>	<i>TIF5p</i>	55%
<i>7</i>	<i>YAP1p</i>	25%

^a The transcriptional activities of selected promoters are obtained from previous report¹.

Supplementary Table 2. Microbial production of isoflavonoids in shake flask cultivations.

Compound	Host	Biosynthetic profile	Precursor feeding	Titer (mg L ⁻¹)	Reference
GEIN	<i>E. coli</i> / <i>S. cerevisiae</i>	Bioconversion	L-Tyrosine	6	2
	<i>E. coli</i>	Bioconversion	NAG	10 mg/g DCW ^a	3
	<i>S. cerevisiae</i>	Bioconversion	NAG	0.5 mg/g DCW	3
	<i>E. coli</i>	Bioconversion	NAG	16.2	4
	<i>E. coli</i>	Bioconversion	NAG	35	5
	<i>S. cerevisiae</i>	Bioconversion	NAG	7.7	6
	<i>S. cerevisiae</i>	Bioconversion	NAG	35	7
	<i>E. coli</i>	Bioconversion	GEIN	20	8
GIN	<i>E. coli</i>	Bioconversion	GEIN	60.5	9
	<i>E. coli</i>	Bioconversion	LIG	18 mg/g DCW	3
DEIN	<i>S. cerevisiae</i>	Bioconversion	LIG	2 mg/g DCW	3
	<i>S. cerevisiae</i>	<i>De novo</i>	None	85.4 (9 mg/g DCW)	This Study
	<i>E. coli</i>	Bioconversion	DEIN	51.7	9
DIN	<i>S. cerevisiae</i>	<i>De novo</i>	None	73.2	This Study
PIN	<i>S. cerevisiae</i>	<i>De novo</i>	None	72.8	This Study

^a DCW, dry cell weight.

Supplementary Table 3. Plasmids used in this study.

Plasmid ID	Relevant characteristics	Reference
Template plasmids		
pCfB0854	Template for At4CL1	10
pQC155	<i>pUC Ori ampR</i> template for At4CL1m (I250L, N404K, I461V)	This study
pCfB0855	Template for At4CL2	10
pQC221	<i>pUC Ori ampR</i> template for GAL3	This study
pQC222	<i>pUC Ori ampR</i> template for GAL3^{S509P}	This study
Gene overexpression		
pSP-GM1	2μm <i>ampR URA3 TEF1p-ADH1t, PGK1p-CYC1t</i>	11
pQC223	2μm <i>ampR URA3 GAL1p-ADH1t, GAL10p-CYC1t</i>	This study
pQC229	2μm <i>ampR URA3 GAL1p-PIUGT43-ADH1t, GAL10p-CYC1t</i>	This study
pQC230	2μm <i>ampR URA3 GAL1p-GmUGT4-ADH1t, GAL10p-CYC1t</i>	This study
pQC231	2μm <i>ampR URA3 GAL1p-ADH1t, GAL10p-GAL3^{S509P}-CYC1t</i>	This study
gRNA vectors		
pMEL10	2μm <i>ampR KIURA3 gRNA-CAN1.Y</i>	12
pROS10	2μm <i>ampR URA3 gRNA-CAN1.Y gRNA-ADE2.Y</i>	12
pQC009	2μm <i>ampR KIURA3 gRNA-XI-5.Y</i>	13
pQC030	2μm <i>ampR URA3 gRNA-XI-1.Y [2x]</i>	13
pQC032	2μm <i>ampR URA3 gRNA-XII-1.Y [2x]</i>	13
pQC033	2μm <i>ampR URA3 gRNA-XII-5.Y [2x]</i>	13
pQC130	2μm <i>ampR URA3 gRNA-XI-2.Y [2x]</i>	13
pQC133	2μm <i>ampR URA3 gRNA-XII-3.Y [2x]</i>	13
pC10-15	2μm <i>ampR URA3 gRNA-OPI1.Y [2x]</i>	14
pQC074	2μm <i>ampR URA3 gRNA-X-2.Y gRNA-XII-2.Y</i>	This study
pQC197	2μm <i>ampR URA3 gRNA-FAS1p.Y [2x]</i>	This study
pQC201	2μm <i>ampR URA3 gRNA-PAH1.Y [2x]</i>	This study
pQC210	2μm <i>ampR URA3 gRNA-HMX1.Y [2x]</i>	This study
pQC214	2μm <i>ampR URA3 gRNA-ROX1.Y [2x]</i>	This study
pQC238	2μm <i>ampR KIURA3 gRNA-ELP3.Y</i>	This study

Supplementary References

1. Keren, L. *et al.* Promoters maintain their relative activity levels under different growth conditions. *Mol Syst Biol* **9**, 701 (2013).
2. Katsuyama, Y., Miyahisa, I., Funa, N. & Horinouchi, S. One-pot synthesis of genistein from tyrosine by coinubation of genetically engineered *Escherichia coli* and *Saccharomyces cerevisiae* cells. *Appl Microbiol Biotechnol* **73**, 1143-1149 (2007).
3. Leonard, E. & Koffas, M.A. Engineering of artificial plant cytochrome P450 enzymes for synthesis of isoflavones by *Escherichia coli*. *Appl Environ Microbiol* **73**, 7246-7251 (2007).
4. Kim, D.H., Kim, B.G., Jung, N.R. & Ahn, J.H. Production of genistein from naringenin using *Escherichia coli* containing isoflavone synthase-cytochrome P450 reductase fusion protein. *J Microbiol Biotechnol* **19**, 1612-1616 (2009).
5. Kim, B.G. Biological synthesis of genistein in *Escherichia coli*. *J Microbiol Biotechnol* **30**, 770-776 (2019).
6. Trantas, E., Panopoulos, N. & Ververidis, F. Metabolic engineering of the complete pathway leading to heterologous biosynthesis of various flavonoids and stilbenoids in *Saccharomyces cerevisiae*. *Metab Eng* **11**, 355-366 (2009).
7. Chemler, J.A., Lim, C.G., Daiss, J.L. & Koffas, M.A. A versatile microbial system for biosynthesis of novel polyphenols with altered estrogen receptor binding activity. *Chem Biol* **17**, 392-401 (2010).
8. He, X.Z., Li, W.S., Blount, J.W. & Dixon, R.A. Regioselective synthesis of plant (iso)flavone glycosides in *Escherichia coli*. *Appl Microbiol Biotechnol* **80**, 253-260 (2008).
9. Koirala, N., Pandey, R.P., Thang, D.V., Jung, H.J. & Sohng, J.K. Glycosylation and subsequent malonylation of isoflavonoids in *E. coli*: strain development, production and insights into future metabolic perspectives. *J Ind Microbiol Biotechnol* **41**, 1647-1658 (2014).
10. Li, M.J. *et al.* *De novo* production of resveratrol from glucose or ethanol by engineered *Saccharomyces cerevisiae*. *Metabolic Engineering* **32**, 1-11 (2015).
11. Partow, S., Siewers, V., Bjorn, S., Nielsen, J. & Maury, J. Characterization of different promoters for designing a new expression vector in *Saccharomyces cerevisiae*. *Yeast* **27**, 955-964 (2010).
12. Mans, R. *et al.* CRISPR/Cas9: a molecular Swiss army knife for simultaneous introduction of multiple genetic modifications in *Saccharomyces cerevisiae*. *FEMS Yeast Res* **15** (2015).
13. Liu, Q. *et al.* Rewiring carbon metabolism in yeast for high level production of aromatic chemicals. *Nat Commun* **10**, 4976 (2019).
14. Liu, Y., Liu, Q., Krivoruchko, A., Khoomrung, S. & Nielsen, J. Engineering yeast phospholipid metabolism for *de novo* oleoylethanolamide production. *Nat Chem Biol* **16**, 197-205 (2020).